A Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma

Brief description of study

This is a study to see if a new medicine called epcoritamab (works by binding to CD3 and CD20 on cells, which brings T cells and follicular lymphoma cells close together and activates the T cells to kill the lymphoma cells) can help patients with a cancer called Diffuse Large B-cell Lymphoma (DLBCL). We want to find out if adding epcoritamab to the usual treatment, R-CHOP (a strong treatment made up of different medicines that work together to make the cancer cells get smaller or even go away completely to treat lymphoma), can make patients with DLBCL stay healthier for longer. The main thing we're looking at is how long it takes for the cancer to come back or for patients to get sicker. We'll compare two groups: one getting epcoritamab with R-CHOP and the other getting just R-CHOP. We're also checking if epcoritamab is safe to use for patients and provides few side effects.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.